JP2019521976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521976A5 JP2019521976A5 JP2018564389A JP2018564389A JP2019521976A5 JP 2019521976 A5 JP2019521976 A5 JP 2019521976A5 JP 2018564389 A JP2018564389 A JP 2018564389A JP 2018564389 A JP2018564389 A JP 2018564389A JP 2019521976 A5 JP2019521976 A5 JP 2019521976A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- composition
- physiological buffer
- vegf
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 29
- 238000009472 formulation Methods 0.000 claims 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 12
- 208000010125 myocardial infarction Diseases 0.000 claims 9
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 4
- 239000000872 buffer Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 150000001768 cations Chemical class 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 102000001974 Hyaluronidases Human genes 0.000 claims 1
- 108050009363 Hyaluronidases Proteins 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 239000011258 core-shell material Substances 0.000 claims 1
- 210000003748 coronary sinus Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000002612 dispersion medium Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- -1 isotonics Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 231100000019 skin ulcer Toxicity 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021049671A JP7167226B2 (ja) | 2016-06-07 | 2021-03-24 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
| JP2022171389A JP2023011733A (ja) | 2016-06-07 | 2022-10-26 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346979P | 2016-06-07 | 2016-06-07 | |
| US62/346,979 | 2016-06-07 | ||
| US201662411091P | 2016-10-21 | 2016-10-21 | |
| US62/411,091 | 2016-10-21 | ||
| US201662432005P | 2016-12-09 | 2016-12-09 | |
| US62/432,005 | 2016-12-09 | ||
| PCT/US2017/036188 WO2017214175A1 (en) | 2016-06-07 | 2017-06-06 | Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049671A Division JP7167226B2 (ja) | 2016-06-07 | 2021-03-24 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521976A JP2019521976A (ja) | 2019-08-08 |
| JP2019521976A5 true JP2019521976A5 (enExample) | 2020-10-01 |
| JP6859369B2 JP6859369B2 (ja) | 2021-04-14 |
Family
ID=59270113
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564389A Active JP6859369B2 (ja) | 2016-06-07 | 2017-06-06 | Ｖｅｇｆ−ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
| JP2021049671A Active JP7167226B2 (ja) | 2016-06-07 | 2021-03-24 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
| JP2022171389A Pending JP2023011733A (ja) | 2016-06-07 | 2022-10-26 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049671A Active JP7167226B2 (ja) | 2016-06-07 | 2021-03-24 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
| JP2022171389A Pending JP2023011733A (ja) | 2016-06-07 | 2022-10-26 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11866475B2 (enExample) |
| EP (2) | EP3971204A1 (enExample) |
| JP (3) | JP6859369B2 (enExample) |
| KR (4) | KR102552543B1 (enExample) |
| CN (2) | CN109790207B (enExample) |
| AU (2) | AU2017277277B2 (enExample) |
| CA (1) | CA3026500A1 (enExample) |
| CY (1) | CY1124667T1 (enExample) |
| DK (1) | DK3464338T3 (enExample) |
| ES (1) | ES2895421T3 (enExample) |
| HR (1) | HRP20211569T1 (enExample) |
| HU (1) | HUE056055T2 (enExample) |
| IL (1) | IL263370A (enExample) |
| LT (1) | LT3464338T (enExample) |
| MA (1) | MA45172B1 (enExample) |
| MX (1) | MX2018015110A (enExample) |
| PL (1) | PL3464338T3 (enExample) |
| PT (1) | PT3464338T (enExample) |
| RS (1) | RS62556B1 (enExample) |
| RU (1) | RU2756313C2 (enExample) |
| SG (2) | SG11201810816QA (enExample) |
| SI (1) | SI3464338T1 (enExample) |
| SM (1) | SMT202100586T1 (enExample) |
| TW (2) | TWI752036B (enExample) |
| WO (1) | WO2017214175A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3464338T (lt) | 2016-06-07 | 2022-01-10 | Modernatx, Inc. | Modifikuota rnr, koduojanti vegf-a polipeptidus, vaisto formos, ir su jomis susiję panaudojimo būdai |
| US11628227B2 (en) * | 2017-07-05 | 2023-04-18 | Wisconsin Alumni Research Foundation | Mineral coated microparticles for gene delivery in chronic wound therapy |
| PL3703658T3 (pl) | 2017-10-31 | 2022-08-22 | Astrazeneca Ab | Nanocząstki lipidowe do dostarczania zmodyfikowanego rna kodującego polipeptyd vegf-a |
| US20220226243A1 (en) * | 2019-05-08 | 2022-07-21 | Astrazeneca Ab | Methods of using lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide and pharmaceutical compositions comprising the same |
| JP7345888B2 (ja) * | 2021-06-17 | 2023-09-19 | 株式会社ニューギン | 遊技機 |
| WO2023061985A2 (en) * | 2021-10-12 | 2023-04-20 | Modernatx, Inc. | Compositions comprising modified rna encoding vegf-a and methods of use |
| WO2023084013A1 (en) * | 2021-11-12 | 2023-05-19 | Modernatx, Inc. | Compositions comprising modified rna encoding vegf-a and methods of use |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004035227A1 (de) * | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| EP1863516A2 (en) | 2005-02-08 | 2007-12-12 | Board of Regents, The University of Texas System | Compositions and methods involving mda-7 for the treatment of cancer |
| WO2010065601A1 (en) * | 2008-12-03 | 2010-06-10 | Amorcyte, Inc. | Infarct area perfusion-improving compositions and methods of vascular injury repair |
| CA2746003C (en) | 2008-12-04 | 2020-03-31 | Opko Curna, Llc | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
| WO2011069529A1 (en) * | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| WO2012103985A2 (en) | 2010-12-16 | 2012-08-09 | Steve Pascolo | Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| JP2014511694A (ja) | 2011-04-03 | 2014-05-19 | ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル | 修飾型ｒｎａ（ｍｏｄ−ｒｎａ）を使用する効率的なインビボタンパク質発現 |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| JP2015510495A (ja) | 2011-12-21 | 2015-04-09 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 器官または器官移植片の生存可能性または寿命を延長する方法 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US20140275229A1 (en) * | 2012-04-02 | 2014-09-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1 |
| US9663564B2 (en) | 2013-03-15 | 2017-05-30 | The Regents Of The University Of California | Vectors and methods to treat ischemia |
| WO2014152211A1 (en) * | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| BR112016016416A2 (pt) * | 2014-01-15 | 2017-10-03 | Hoffmann La Roche | VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS |
| WO2016118725A1 (en) | 2015-01-23 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| DK3350157T3 (da) | 2015-09-17 | 2022-02-14 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler |
| LT3464338T (lt) | 2016-06-07 | 2022-01-10 | Modernatx, Inc. | Modifikuota rnr, koduojanti vegf-a polipeptidus, vaisto formos, ir su jomis susiję panaudojimo būdai |
| US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
| MX389934B (es) | 2016-12-09 | 2025-03-20 | Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V | Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos. |
| PL3703658T3 (pl) | 2017-10-31 | 2022-08-22 | Astrazeneca Ab | Nanocząstki lipidowe do dostarczania zmodyfikowanego rna kodującego polipeptyd vegf-a |
| EP3965797A1 (en) | 2019-05-08 | 2022-03-16 | AstraZeneca AB | Compositions for skin and wounds and methods of use thereof |
-
2017
- 2017-06-06 LT LTEPPCT/US2017/036188T patent/LT3464338T/lt unknown
- 2017-06-06 KR KR1020237003204A patent/KR102552543B1/ko active Active
- 2017-06-06 PL PL17734885T patent/PL3464338T3/pl unknown
- 2017-06-06 SI SI201730935T patent/SI3464338T1/sl unknown
- 2017-06-06 US US16/305,224 patent/US11866475B2/en active Active
- 2017-06-06 MX MX2018015110A patent/MX2018015110A/es unknown
- 2017-06-06 ES ES17734885T patent/ES2895421T3/es active Active
- 2017-06-06 JP JP2018564389A patent/JP6859369B2/ja active Active
- 2017-06-06 RS RS20211280A patent/RS62556B1/sr unknown
- 2017-06-06 SG SG11201810816QA patent/SG11201810816QA/en unknown
- 2017-06-06 RU RU2018147229A patent/RU2756313C2/ru active
- 2017-06-06 HR HRP20211569TT patent/HRP20211569T1/hr unknown
- 2017-06-06 CA CA3026500A patent/CA3026500A1/en active Pending
- 2017-06-06 PT PT177348851T patent/PT3464338T/pt unknown
- 2017-06-06 SM SM20210586T patent/SMT202100586T1/it unknown
- 2017-06-06 CN CN201780048447.8A patent/CN109790207B/zh active Active
- 2017-06-06 MA MA45172A patent/MA45172B1/fr unknown
- 2017-06-06 WO PCT/US2017/036188 patent/WO2017214175A1/en not_active Ceased
- 2017-06-06 AU AU2017277277A patent/AU2017277277B2/en not_active Ceased
- 2017-06-06 EP EP21186195.0A patent/EP3971204A1/en not_active Withdrawn
- 2017-06-06 KR KR1020227008509A patent/KR102494499B1/ko active Active
- 2017-06-06 CN CN202310693718.2A patent/CN116606861A/zh active Pending
- 2017-06-06 SG SG10202012175YA patent/SG10202012175YA/en unknown
- 2017-06-06 HU HUE17734885A patent/HUE056055T2/hu unknown
- 2017-06-06 KR KR1020197000227A patent/KR102376245B1/ko active Active
- 2017-06-06 DK DK17734885.1T patent/DK3464338T3/da active
- 2017-06-06 EP EP17734885.1A patent/EP3464338B1/en active Active
- 2017-06-06 KR KR1020237022229A patent/KR20230107891A/ko not_active Ceased
- 2017-06-07 TW TW106118838A patent/TWI752036B/zh not_active IP Right Cessation
- 2017-06-07 TW TW110145699A patent/TWI818375B/zh not_active IP Right Cessation
-
2018
- 2018-11-29 IL IL263370A patent/IL263370A/en unknown
-
2021
- 2021-03-24 JP JP2021049671A patent/JP7167226B2/ja active Active
- 2021-10-14 CY CY20211100889T patent/CY1124667T1/el unknown
-
2022
- 2022-10-26 JP JP2022171389A patent/JP2023011733A/ja active Pending
-
2023
- 2023-07-28 AU AU2023208200A patent/AU2023208200A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521976A5 (enExample) | ||
| HRP20211569T1 (hr) | Modificirana rna koja kodira vegf-a polipeptide, formulacije, i upotrebe koje se na njih odnose | |
| Thompson et al. | Cardio-pericardiopexy; the surgical treatment of coronary arterial disease by the establishment of adhesive pericarditis | |
| US20070093748A1 (en) | Methods and systems for treating injured cardiac tissue | |
| US20110117195A1 (en) | Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers | |
| JPWO2018139562A1 (ja) | 心筋症、陳旧性心筋梗塞および慢性心不全の治療薬 | |
| WO2022076556A3 (en) | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 | |
| JP2023171773A (ja) | 心臓機能を改善するための組成物および方法 | |
| JP2010163457A (ja) | 脈管形成に有効な単位用量のｆｇｆ−２および使用方法 | |
| CN101310766B (zh) | 神经调节蛋白的新用途 | |
| CN104862281A (zh) | 表达bFGF和PDGF-BB的重组载体修饰的间充质干细胞及其制备方法和用途 | |
| KR20180044235A (ko) | 조직 병변 치료용 조성물 | |
| Fazel et al. | Current status of cellular therapy for ischemic heart disease | |
| EA009390B1 (ru) | Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом | |
| Takehara | Cell therapy for cardiovascular regeneration | |
| Bahramian et al. | The effects of exercise training intensity on the expression of C/EBPβ and CITED4 in rats with myocardial infarction | |
| Aceves et al. | Autologous CXCR4+ hematopoietic stem cells injected into the scar tissue of chronic myocardial infarction patients normalizes tissue contractility and perfusion | |
| JP2015061536A5 (enExample) | ||
| JP2005206544A (ja) | 筋肉再生剤 | |
| RU2250772C1 (ru) | Способ лечения неоперабельных кардиологических больных | |
| CN103239714B (zh) | 用于治疗缺血性疾病的蛋白质及药物组合物 | |
| US20130164847A1 (en) | Use of a protein tyrosine kinase inhibitor for inducing the differentiation of mesenchymal stem cells into cardiogenic cells | |
| CN113425731B (zh) | 一种增效干细胞治疗心梗的药物及其应用 | |
| WO2012138043A2 (en) | Therapeutic composition containing endothelin as an active component | |
| Herdrich et al. | Progenitor cells for the treatment of acute myocardial infarction |